There is limited existing research on the incidence of metabolic syndrome in individuals with chronic obstructive pulmonary disease (COPD). However, a recent study aimed to determine the incidence of metabolic syndrome in men with COPD who experience airway obstruction.
There is limited existing research on the incidence of metabolic syndrome in individuals with chronic obstructive pulmonary disease (COPD). However, a recent study aimed to determine the incidence of metabolic syndrome in men with COPD who experience airway obstruction.
The study used data representing 4 years of follow-ups from the Ansung-Ansan cohort—a community-based sample that was evaluated in the Korean Genome and Epidemiology study (KoGES). The Ansung-Ansan cohort used in the study consisted of 6184 adults, who were at least 40 years old and underwent spirometry.
Throughout the analysis, the researchers defined airway obstruction as mean forced expiratory volume in 1 second (FEV1) <70%. Metabolic syndrome was defined by the National Cholesterol Education Program Adult Treatment Panel III guidelines. Lung function tests were performed using a portable spirometer in addition to each patient undergoing pulmonary function testing.
“Many of the previous studies regarding MetS [metabolic syndrome] in COPD were cross-sectional and primarily focused on the prevalence, rather than the incidence, of MetS in patients with COPD,” the study noted. “Thus, the present study aimed to evaluate the incidence and characteristics of MetS in COPD patients using data from a large community-based cohort.”
A total of 3604 subjects were included in the study and based on the treatment guidelines, a total of 419 patients were newly diagnosed with metabolic syndrome during follow-up. The analysis of the data revealed that metabolic syndrome was more frequent in COPD subjects, when compared to non-COPD subjects, in both sexes. Specifically, for men, the risk for metabolic syndrome was higher in individuals with airflow obstruction than in those without obstruction.
Furthermore, the incidence of metabolic syndrome in COPD patients was most influenced by fasting blood glucose level and high blood pressure. Also, prevalence was higher in older, male COPD patients who demonstrated higher body mass index and severe smoking status.
“The incidence of MetS was higher in the airflow obstruction group, even after adjustment for other confounding factors, including age, BMI, smoking, and physical activity, in male subjects,” the researchers said. “This finding is consistent with previous studies that have reported an increased prevalence of MetS in patients with COPD.”
The researchers noted that their research was limited as it did not consider certain comorbidities, such as cardiovascular disease and malignancies. The researchers also suggested the need for future longitudinal and interventional studies with larger sample sizes that investigate the relationship between airflow obstruction and the incidence of metabolic syndrome in the general population.
Reference
Kim CY, Park Y, Leem AY, et al. Relationship between airway obstruction and incidence of metabolic syndrome in Korea: a community-based cohort study. [published online June 28, 2018]. Int J Chron Obstruct Pulmon Dis. doi.org: 10.2147/COPD.S157453
Ineligibility, Limitations to PR Uptake in Patients With AECOPD
October 15th 2024Two posters at the CHEST 2024 annual meeting revealed that 18% of eligible patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) participated in post-discharge pulmonary rehabilitation (PR), with ineligibility significantly limiting uptake.
Read More
A Pulmonologist on Why You Should Think About Respiratory Health and the Lungs
November 16th 2021On this episode of Managed Care Cast, we speak with MeiLan K. Han, MD, MS, the author of a book released this month called Breathing Lessons: A Doctor’s Guide to Lung Health. Han, a pulmonologist, gives an inside tour of the lungs and how they work, zooms out to examine the drivers of poor respiratory health, and addresses policy changes that are needed to improve lung health.
Listen
FDA Approves Dupilumab as First Biologic Treatment for COPD
September 27th 2024The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype to significantly help reduce exacerbations and improve lung function.
Read More
Social Frailty Indirectly Affects Anxiety, Depression in Patients With AECOPD Through Social Support
September 11th 2024Social frailty in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) does not directly impact anxiety or depression but influences these conditions indirectly through social support.
Read More